SGI-1776

SGI-1776 is an inhibitor of Pim kinases, with IC50s of 7 nM, 363 nM, and 69 nM for Pim-1, Pim-2 and Pim-3, respectively[1][2][3][4].

Product Specifications

CAS Number

[1173928-26-1]

UNSPSC

12352005

Target

Apoptosis; Autophagy; Pim

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; JAK/STAT Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/sgi-1776-1.html

Solubility

10 mM in DMSO

Smiles

CN1CCC(CC1)CNC2=NN3C(C=C2)=NC=C3C4=CC=CC(OC(F)(F)F)=C4.O=S(O)(O)=O.O=S(O)(O)=O

Molecular Formula

C20H26F3N5O9S2

Molecular Weight

601.57

References & Citations

[1]Chen LS, et al. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood, 2011, 118 (3), 693-702.|[2]Xie J, et al. SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating Pim-1. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014 Jul;39 (7) :649-57|[3]Park YK, et al. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes. Int J Mol Med. 2016 Jan;37 (1) :157-64|[4]Hou X, et al. Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776. Exp Cell Res. 2017 Mar 15;352 (2) :403-411.